Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06655545
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
None
First Post:
2024-10-22
Brief Title:
18F-fluoroestradiol 18F-FES PETCT Guided First-line Treatment for HRHER2- Metastatic Breast Cancer Patients
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Single-center Real-world Study Exploring the Guidance of FES-PET for First-line Treatment of HR Positive HER2 Negative Unresectable or Metastatic Breast Cancer Patients
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A single-center real world study to evaluate the role of FES-PET in guiding the first-line treatment of HRHER2- MBC patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None